Roughly 40% of myelofibrosis patients on ruxolitinib develop a suboptimal response, and for those who eventually discontinue, median overall survival collapses to somewhere between one and two years. That clinical reality is what Ipsen is betting $450 million upfront on, with milestone payments that could push the total to $1.75 billion, in its acquisition of Kartos Therapeutics announced Sunday.
The asset at the center of the deal is navtemadlin, an oral MDM2 inhibitor designed to restore p53 tumor-suppressor function. Its mechanism is deliberately orthogonal to JAK inhibition: rather than replacing ruxolitinib, which has anchored myelofibrosis treatment since 2011, navtemadlin is positioned as an add-on to pull suboptimal responders into a clinical response. Phase Ib/II data presented at EHA 2023 give that thesis some traction. In a small but meaningful cohort of ruxolitinib non-responders (n=19), 42% hit at least a 25% reduction in spleen volume by Week 24, and 71% of evaluable patients showed a 20% or greater drop in driver variant allele frequency. That last number matters most: it gestures toward disease modification, not just symptom management, and it is the biological argument Ipsen is buying.
The pivotal test is the ongoing Phase III POIESIS trial, designed to enroll more than 600 patients across more than 250 sites globally, making it the largest trial conducted in this disease to date. Top-line data are expected in 2027, which puts a potential regulatory submission in the 2027-to-2028 window and commercial accretion, by Ipsen’s own projection, no earlier than 2029. The myelofibrosis field already includes approved JAK inhibitors beyond ruxolitinib, among them fedratinib, pacritinib, and momelotinib, each carving out distinct patient segments by line of therapy and cytopenia profile. Navtemadlin’s add-on, combination positioning does not directly displace any of those agents, but it does introduce a new competitive layer for the ruxolitinib-maintained patient population, which remains the largest segment in the market.
The single number worth watching as POIESIS matures is bone marrow fibrosis improvement by central review. The Phase Ib/II signal (57% achieving a grade or better reduction at Week 24) is suggestive but based on just seven evaluable patients. If POIESIS confirms that histologic endpoint at scale, it substantially strengthens the regulatory and commercial case; if the signal attenuates in a larger, more heterogeneous population, Ipsen’s $1.75 billion thesis becomes considerably harder to defend.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
